Fosfomycin/molgramostim- Reponex Pharmaceuticals
Alternative Names: RNX-023Latest Information Update: 08 Aug 2024
At a glance
- Originator Reponex Pharmaceuticals
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antibronchitics; Antifibrotics; Antiulcers; Chemoprotectants; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Recombinant proteins; Small molecules
- Mechanism of Action Cell wall inhibitors; Granulocyte macrophage colony stimulating factor replacements; Peptidoglycan inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Crohn's disease
- Preclinical Varicose ulcer; Wounds
Most Recent Events
- 26 Dec 2022 No recent reports on development identified – phase II for Crohn's disease in Denmark (Intraluminal) (Reponex Pharmaceuticals pipeline, December 2022)
- 07 Oct 2020 Preclinical trials in Varicose ulcer in Denmark (unspecified route) (Reponex Pharmaceuticals pipeline, October 2020)
- 07 Oct 2020 Preclinical trials in Wounds in Denmark (unspecified route) (Reponex Pharmaceuticals pipeline, October 2020)